The estimated Net Worth of Jacqueline Sybil Papkoff is at least $5.22 Milione dollars as of 14 December 2020. Jacqueline Papkoff owns over 1,297 units of Assembly Biosciences Inc stock worth over $649,386 and over the last 7 years he sold ASMB stock worth over $56,468. In addition, he makes $4,510,200 as Senior Vice President e Chief Scientific Officer Microbiome at Assembly Biosciences Inc.
Sign up
Jacqueline Papkoff ASMB stock SEC Form 4 insiders trading
Jacqueline has made over 3 trades of the Assembly Biosciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 1,297 units of ASMB stock worth $7,977 on 14 December 2020.
The largest trade he's ever made was selling 1,460 units of Assembly Biosciences Inc stock on 13 December 2019 worth over $30,660. On average, Jacqueline trades about 573 units every 52 days since 2018. As of 14 December 2020 he still owns at least 37,364 units of Assembly Biosciences Inc stock.
You can see the complete history of Jacqueline Papkoff stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jacqueline Papkoff biography
Dr. Jacqueline Sybil Papkoff Ph.D. serves as Senior Vice President, Chief Scientific Officer Microbiome of the Company. Dr. Papkoff was Senior Vice President, Research at Evelo Biosciences, Inc. from May 2016 to October 2017. From January 2013 to May 2016, Dr. Papkoff was Vice President, Immunology Scientific Innovation at Johnson & Johnson California Innovation Center as a representative of the Janssen immunology therapeutic area. From 2008 to 2012, Dr. Papkoff was an independent biotherapeutic research and development consultant to biotechnology and pharmaceutical companies. In 2006 and 2007, Dr. Papkoff was Executive Vice President Therapeutics, Chief Scientific Officer at CFD Therapeutics, Inc. From 2002 until 2006, Dr. Papkoff was initially Vice President, Discovery and later Executive Vice President, Therapeutics at diaDexus, Inc. Dr. Papkoff received a B.A. in Biology with highest honors from the University of California, Santa Cruz and received a Ph.D. in Biology from the University of California, San Diego.
What is the salary of Jacqueline Papkoff?
As the Senior Vice President e Chief Scientific Officer Microbiome of Assembly Biosciences Inc, the total compensation of Jacqueline Papkoff at Assembly Biosciences Inc is $4,510,200. There are 1 executives at Assembly Biosciences Inc getting paid more, with John McHutchison having the highest compensation of $7,007,210.
How old is Jacqueline Papkoff?
Jacqueline Papkoff is 64, he's been the Senior Vice President e Chief Scientific Officer Microbiome of Assembly Biosciences Inc since 2018. There are 5 older and 12 younger executives at Assembly Biosciences Inc. The oldest executive at Assembly Biosciences Inc is Alan Lewis, 74, who is the Independent Director.
What's Jacqueline Papkoff's mailing address?
Jacqueline's mailing address filed with the SEC is C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD., FOURTH FLOOR, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Assembly Biosciences Inc
Over the last 10 years, insiders at Assembly Biosciences Inc have traded over $1,523,622 worth of Assembly Biosciences Inc stock and bought 1,245,980 units worth $1,060,065 . The most active insiders traders include Sciences, Inc. Gilead, Myron Z Holubiak e Helen Susan Kim. On average, Assembly Biosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $389,399. The most recent stock trade was executed by Nicole S White on 2 August 2024, trading 785 units of ASMB stock currently worth $11,171.
What does Assembly Biosciences Inc do?
assembly biosciences, inc. (nasdaq: asmb) is a public clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and novel oral live biotherapeutics for disorders associated with the microbiome. assembly is developing two innovative platform programs: an hbv program advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. assembly’s hbv program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic hbv. the company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current good manufacturing practices and a patent-pending delivery system, gemicel®, which allows for targeted ora
What does Assembly Biosciences Inc's logo look like?
Complete history of Jacqueline Papkoff stock trades at Assembly Biosciences Inc
Assembly Biosciences Inc executives and stock owners
Assembly Biosciences Inc executives and other stock owners filed with the SEC include:
-
John McHutchison,
President, Chief Executive Officer, Director -
Jacqueline Papkoff,
Senior Vice President, Chief Scientific Officer Microbiome -
Thomas Joseph Russo,
Chief Financial Officer -
Luisa Stamm,
Chief Medical Officer -
Dr. John G. McHutchison A.O., FRACP, M.D.,
CEO, Pres & Director -
Jason A. Okazaki,
Chief Operating Officer -
Dr. William E. Delaney IV, Ph.D.,
Chief Scientific Officer -
William Ringo,
Non-Executive Independent Chairman of the Board -
Myron Holubiak,
Independent Director -
Alan Lewis,
Independent Director -
Anthony Altig,
Independent Director -
Susan Mahony,
Independent Director -
Richard DiMarchi,
Independent Director -
Helen Kim,
Independent Director -
Nicole White,
Senior Vice President - Pharmaceutical Development and Manufacturing -
Gina Consylman,
Independent Director -
Jason Okazaki,
Chief Legal and Business Officer -
William Delaney,
Chief Scientific Officer - Virology -
Steven Knox,
Senior Vice President - Clinical Development -
David Houck,
Senior Vice President - Product Development and Portfolio Management -
Michele Anderson,
Chief Devel. Officer -
Dr. Tharaknath Rao,
Head of Microbiome Clinical Devel. & Sr. VP -
Dr. Richard J. Colonno,
Sr. Advisor -
Jennifer A. Troia MHROD, SHRM-SCP, SPHR,
Chief HR Officer -
Lauren Glaser,
Sr. VP of Investor Relations & Corp. Affairs -
Michael P. Samar,
CFO & Principal Accounting Officer -
Dr. Adam Zlotnick,
Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board -
Dr. Uri A. Lopatin M.D.,
Co-Founder and Clinical & Scientific Advisor -
Graham K Cooper,
See Remarks -
Mark Auerbach,
Director -
David Jonathan Barrett,
See Remarks -
Thomas E Rollins,
Chief Development Officer -
Uri A Lopatin,
Chief Medical Officer -
Michael Houghton,
-
Derek A Small,
Director -
Richard James Colonno,
EVP & CSO, Virology Ops -
Capital Fund Qualified, L.P...,
10% owner -
Lisa Johnson Pratt,
-
Anuj Gaggar,
Chief Medical Officer -
Adam Zlotnick,
10% owner -
Sciences, Inc. Gilead,
10% owner -
Michael P. Samar,
Chief Financial Officer -
Jeanette M Bjorkquist,
Principal Accounting Officer -
Alexander Schornstein,
10% owner